Cellectis (NASDAQ:CLLS) Posts Earnings Results, Misses Expectations By $0.43 EPS

Cellectis (NASDAQ:CLLS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.43), FiscalAI reports. The business had revenue of $5.44 million during the quarter, compared to analysts’ expectations of $15.61 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Cellectis Trading Down 3.6%

Shares of NASDAQ CLLS traded down $0.05 during trading on Thursday, hitting $1.33. 40,281 shares of the company traded hands, compared to its average volume of 59,406. The firm has a market capitalization of $133.45 million, a P/E ratio of -2.05 and a beta of 3.21. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The company has a 50-day moving average price of $1.53 and a 200-day moving average price of $2.95. Cellectis has a 1 year low of $0.88 and a 1 year high of $5.45.

Analyst Ratings Changes

CLLS has been the topic of several recent analyst reports. Citizens Jmp downgraded Cellectis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 15th. Robert W. Baird lowered their price target on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, September 15th. Weiss Ratings raised shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Wells Fargo & Company dropped their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 15th. Finally, Barclays lowered shares of Cellectis from an “overweight” rating to an “underweight” rating and cut their price objective for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.46.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.